All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

The Noninvasive Biomarker KIM-1 Is Front and Center in RCC Investigations

August 15th 2024

Brian Rini, MD, and Robert Uzzo, MD, MBA, FACS, highlight the utility of the potential biomarker KIM-1 in renal cell carcinoma.

Pirtobrutinib Displays Efficacy in Patients With Richter Transformation

August 15th 2024

Pirtobrutinib was safe and demonstrated activity in patients with Richter transformation, according to a subgroup analysis of the BRUIN trial.

Targeted Therapy Combinations Could Represent Next Wave of Treatments in Follicular Lymphoma

August 15th 2024

Geoffrey Shouse, DO, PhD, discusses the benefits of utilizing targeted therapy approaches in the treatment of patients with follicular lymphoma.

Daily Use of E-Cigarettes Linked to Higher Cigarette Quit Rates, Roswell Park Research Shows

August 14th 2024

A study led by experts at Roswell Park Comprehensive Cancer Center suggests that e-cigarette use may help some people quit using combustible cigarettes.

FDA Approves Axatilimab for Chronic Graft-vs-Host Disease

August 14th 2024

The FDA has approved axatilimab for adult and pediatric patients with cGVHD who have progressed on at least 2 prior lines of systemic therapy.

Deltacel Plus Radiation Wins FDA Fast Track Designation for Pretreated Metastatic NSCLC

August 14th 2024

The FDA has granted fast track designation to Deltacel in combination with low-dose radiation for pretreated metastatic non–small cell lung cancer.

VP-315 Induces Reductions in Tumor Size in Basal Cell Carcinoma

August 14th 2024

Treatment with VP-315 led to reductions in tumor size in patients with basal cell carcinoma.

Durvalumab-Based Combos Win EU Approval for Advanced/Recurrent Endometrial Cancer

August 14th 2024

Durvalumab plus chemotherapy, then durvalumab with or without olaparib, was approved in Europe for select advanced/recurrent endometrial cancer.

FDA Grants Fast Track Status to AC699 for ER+/HER2–, ESR1-Mutated Breast Cancer

August 14th 2024

AC699 has won fast track designation from the FDA for select patients with ER-positive, HER2-negative, ESR1-mutated breast cancer.

FDA Approval Sought for UGN-102 in Low-Grade, Intermediate-Risk NMIBC

August 14th 2024

A new drug application has been submitted to the FDA for UGN-102 inlow-grade, intermediate-risk non–muscle-invasive bladder cancer.

Analyzing the “RAS Pie” for Methods to Target Mutations in GI Cancers

August 14th 2024

The acceleration of targeted therapy drug development has led investigators to home in on RAS mutations as agents are approved in colorectal cancer.

Cannabis-Use Disorder Demonstrates a Link With Developing Head and Neck Cancer

August 14th 2024

Cannabis-related disorder was associated with the development of head and neck cancer in adults.

ASCO Issues Statement Calling for Streamlined Clinical Trial Requirements

August 14th 2024

ASCO has released a research statement outlining 4 recommendations to decentralize clinical trials and improve patient access to these studies.

Emerging ADCs and Immunotherapy Shake Up Triple-Negative Breast Cancer Management

August 13th 2024

Linda T. Vahdat, MD, discusses the use of ADCs in metastatic TNBC and how neoadjuvant immunotherapy performs in patients with early-stage TNBC.

Elranatamab Shows Activity, Safety as Compassionate Use in R/R Multiple Myeloma

August 13th 2024

Mohamad Mohty, MD, PhD, discusses real-world data for elranatamab in relapsed/refractory multiple myeloma in the French compassionate use program.

Fox Chase Cancer Center Welcomes Aitziber Buque Martinez

August 13th 2024

Fox Chase Cancer Center announces Aitziber Buque Martinez, PhD, as an assistant professor in the Cancer Signaling and Microenvironment Research Program.

Enrollment to Discontinue for SELECT-AML-1 Trial of Tamibarotene Triplet in Newly Diagnosed RARA+ AML

August 13th 2024

Enrollment will discontinue for the SELECT-AML-1 trial of tamibarotene/venetoclax/azacitidine in newly diagnosed, RARA-positive acute myeloid leukemia.

T-DXd Wins Conditional Approval in China for Pretreated HER2+ Gastric/GEJ Cancer

August 13th 2024

Trastuzumab deruxtecan earned conditional approval in China for HER2-positive gastric/gastroesophageal junction cancer after at least 2 lines of therapy.

Vebreltinib Induces Responses in non-CNS MET Fusion+ Solid Tumors

August 13th 2024

Vebreltinib demonstrated preliminary activity in patients with non–central nervous system solid tumors harboring MET fusions.

Immune Therapy, EGFR Inhibition Take Hold of Stage III NSCLC

August 13th 2024

Clinicians specializing in caring for patients with lung cancer discussed clinical trial updates on agents in stage III NSCLC.